Gardasil Vaccine Long-Term Side Effects

Large-scale studies following millions of vaccinated people for up to a decade or more consistently show that Gardasil carries no unexpected serious long-term risks. The most rigorous synthesis of the evidence, a Cochrane review pooling 39 studies with over 97,000 participants, found essentially no difference in serious adverse events between HPV vaccine recipients and control groups over follow-up periods stretching to six years. That does not mean the vaccine causes zero side effects; short-term reactions like injection-site pain and brief fainting episodes are well documented. But when people search for “long-term side effects,” they are usually worried about autoimmune diseases, fertility problems, neurological damage, or chronic conditions developing months or years after the shot. The evidence on each of those concerns is extensive and worth walking through.

What Nearly Two Decades of Surveillance Data Show

The United States runs a passive reporting system called VAERS, managed jointly by the CDC and FDA, where anyone can submit a report after a vaccination. Between 2006 and 2024, about 76,500 reports related to HPV vaccines met researchers’ inclusion criteria. Of those, roughly 83% of all adverse events appeared within the first week, and more than 60% showed up the same day as the shot. The most common flagged signals were not disease-related at all: for Gardasil and Gardasil 9, the top signals were administrative issues like incorrect scheduling or improper storage, not clinical harm.¹

VAERS has a well-known limitation: it is a passive system, meaning anyone can file a report regardless of whether the vaccine actually caused the event. It captures signals that need further investigation, not proof of causation. Underreporting is also built into the system’s design.² That means raw VAERS counts should not be treated as an accurate tally of how often something happens. To determine whether a signal represents a real risk, researchers turn to controlled studies, large registry analyses, and systematic reviews. Those are the studies that actually tell us about long-term safety.

Autoimmune Disease Risk

One of the most persistent fears is that HPV vaccination could trigger autoimmune diseases such as lupus, rheumatoid arthritis, or type 1 diabetes. Several large studies have directly tested this idea, and the overall picture is reassuring. A cohort study of nearly one million adolescent girls in Denmark and Sweden tracked autoimmune, neurological, and blood-clotting events for up to four years after vaccination. After adjusting for multiple comparisons, the researchers found no consistent safety signals.³

A French study was even larger, following over 2.25 million girls for an average of about 33 months. In that population, the overall rate of autoimmune diseases was not elevated among those who received the HPV vaccine. The one exception was a small signal for Guillain-Barré syndrome: 20 cases among vaccinated girls compared to 23 among the unvaccinated, which translated to a roughly fourfold higher rate in the vaccinated group.⁴ The absolute numbers were tiny, and other large studies have not consistently replicated this finding, as discussed below. But it is worth flagging because Guillain-Barré syndrome is the one autoimmune condition that has repeatedly appeared in the conversation around HPV vaccines.

When researchers studied vaccinated boys in Denmark, the combined rate of 39 autoimmune diseases was nearly identical between the vaccinated and unvaccinated groups. Two very rare conditions, vitiligo and narcolepsy, appeared slightly more often in vaccinated boys, but those signals were based on just two and three cases respectively, making them too small to draw firm conclusions from.⁵ In 2013, the WHO’s Global Advisory Committee on Vaccine Safety reviewed the international evidence on autoimmune diseases and HPV vaccination and concluded that the data showed no increased risk, including for multiple sclerosis.⁶

Demyelinating Diseases and Guillain-Barré Syndrome

Diseases where the immune system attacks nerve coatings, known as demyelinating diseases, include multiple sclerosis and optic neuritis. A meta-analysis that combined results from 11 pharmacoepidemiologic studies found no association between HPV vaccination and central demyelination, with the pooled estimate sitting right at the “no effect” mark. The same held true when the researchers looked at multiple sclerosis and optic neuritis separately.⁷

Guillain-Barré syndrome, which affects peripheral rather than central nerves, has been harder to pin down. The French cohort study mentioned earlier suggested a possible increase, but the U.S. Vaccine Safety Datalink, a more tightly controlled system than VAERS, tracked nearly 2.8 million Gardasil doses and confirmed only one case of GBS in a male and zero in females. That rate was actually below the background rate expected in the general population.⁸ The discrepancy between the French signal and the American data may reflect differences in study design, population characteristics, or simply the statistical noise that comes with tracking extremely rare conditions. Even in the French data, the absolute risk was about one extra case per 100,000 vaccinated person-years, which is vanishingly small.

POTS, Dysautonomia, and Complex Regional Pain Syndrome

Postural orthostatic tachycardia syndrome, a condition where standing up causes abnormal heart rate spikes and symptoms like dizziness and fatigue, has been reported after HPV vaccination in case reports and small case series. One published case described a 14-year-old girl developing POTS with chronic fatigue two months after Gardasil.⁹ A Danish study that gathered referrals of patients suspected of having developed symptoms after HPV vaccination found that 21 of 35 patients met the diagnostic criteria for POTS.¹⁰

These reports are real, and the suffering of the individuals involved is not in question. The difficulty is establishing causation. POTS typically emerges during adolescence, the exact age window when HPV vaccination happens, and it can also be triggered by viral infections, rapid growth, and other common events. The European Medicines Agency conducted a detailed review in 2015 and concluded that the available data did not support a causal link between HPV vaccines and POTS or another suspected condition, complex regional pain syndrome (CRPS). A case-cohort analysis of U.S. insurance claims data found that the risk of CRPS was not elevated at 30, 90, or 180 days after vaccination after accounting for confounders like prior injury and infection.¹¹

Some of the clustering of reported symptoms after vaccination in school settings has been attributed to what researchers now call “immunization stress-related responses.” In São Paulo, Brazil, after the national HPV vaccination program launched, clusters of symptoms in vaccinated adolescents were medically investigated and classified as stress-related rather than vaccine-caused.¹² That does not mean the symptoms were “made up.” Stress-related physiological responses are genuine physical events, but they are caused by the anxiety of the vaccination experience rather than the vaccine’s contents.

Fertility and Ovarian Function

A claim that Gardasil causes premature ovarian insufficiency, sometimes called “early menopause,” gained traction online after a handful of case reports were published. Two substantial studies have since addressed this. A systematic review and meta-analysis found no significant risk of premature ovarian insufficiency between those who received the quadrivalent HPV vaccine and unvaccinated controls.¹³ A nationwide cohort study published in JAMA Network Open compared vaccinated and unvaccinated individuals and found an adjusted hazard ratio of 0.96, meaning the vaccinated group had essentially the same rate of ovarian insufficiency as the unvaccinated group.¹⁴ The evidence is clear: HPV vaccination does not appear to harm ovarian function.

Pregnancy Safety When Vaccinated Before or During Pregnancy

Gardasil is not recommended during pregnancy, but not because it has been shown to cause harm. It is a non-live vaccine, so it cannot cause an infection. The precaution exists mainly because the data is more limited than for non-pregnant populations. When researchers have looked at pregnancies that happened to coincide with vaccination, the results are reassuring. A large matched study published in the New England Journal of Medicine found no increased risk of major birth defects, spontaneous abortion, preterm birth, low birth weight, or stillbirth among women exposed to the quadrivalent HPV vaccine during pregnancy.¹⁵ A separate analysis confirmed these findings, detecting no increased risk of adverse pregnancy or infant outcomes after inadvertent exposure.¹⁶ If you discover you were pregnant when you received a dose, the standard advice is simply to delay the remaining doses until after delivery.

Differences Between Gardasil Versions

The original Gardasil targeted four HPV types. Gardasil 9, which replaced it and is now the only version available in the United States, covers five additional cancer-causing HPV types. That broader coverage comes with a slightly higher antigen and adjuvant load in each dose. In clinical trials, the two versions showed comparable safety profiles, though injection-site swelling was somewhat more common with Gardasil 9.¹⁷

Post-marketing surveillance has picked up a somewhat broader range of reported signals for Gardasil 9 compared to the original, particularly around dysautonomia-related complaints and autoimmune symptoms. But the researchers who analyzed nearly a decade of VAERS data for Gardasil 9 described the overall safety signal as “reassuring.”¹⁸ The practical takeaway is that the newer vaccine may cause a bit more local soreness and swelling but does not introduce fundamentally different long-term risks.

Long-Term Follow-Up in Males

Most early safety data focused on girls and young women, because cervical cancer was the primary target. But HPV also causes cancers of the throat, anus, and penis, so boys and young men are now routinely vaccinated. A 10-year follow-up of a randomized trial in men reported no vaccine-related serious adverse events over the entire study period.¹⁹ An eight-year interim analysis of Gardasil 9 in boys and girls aged 9 to 15 likewise found no vaccine-related serious adverse events or deaths.²⁰ A separate long-term study in both genders followed participants for eight years post-vaccination and observed no new significant serious adverse events.²¹ The safety profile in males matches what has been seen in females.

How Media Coverage Has Distorted the Risk Picture

Denmark offers a useful case study of how public perception can diverge from evidence. HPV vaccination uptake there was initially high, but it fell sharply after 2013, when Danish media ran prominent stories about young women who developed chronic symptoms they attributed to Gardasil. Research later showed a strong correlation between the volume of negative media coverage and the decline in vaccination rates.²² A separate analysis found that spikes in news coverage and Google searches about Gardasil side effects were followed by increases in adverse event reports to VAERS, suggesting that some reporting was driven by media awareness rather than new medical events.²³

None of this means that individual patients’ experiences should be dismissed. People who develop new health problems after any medical intervention deserve proper clinical evaluation. But the pattern in Denmark illustrates a genuine tension in vaccine safety communication: the passive reporting systems that detect early safety signals can also amplify perceived risks when media attention drives more reporting, which in turn generates more media attention. Denmark eventually stabilized its vaccination rates after a coordinated public health effort, but the dip left a cohort of under-vaccinated girls at increased risk for HPV-related cancers.

How the Cochrane Review Summarizes the Evidence

The most authoritative synthesis of HPV vaccine safety comes from a Cochrane systematic review, which is widely considered the gold standard for evaluating medical evidence. Pooling data from 39 studies involving over 97,000 participants, the review found that the rate of serious adverse events was virtually identical between HPV vaccine groups and control groups, with follow-up extending to 72 months. The certainty of the evidence was rated high.²⁴ An earlier review of randomized controlled trials reached the same conclusion, noting that the most common complaint was self-limiting injection-site pain and that no increased risk of autoimmune disease had emerged from long-term observation.²⁵

Unexpected Health Benefits Beyond HPV Prevention

Recent research has turned up findings that complicate the simple “risks versus benefits” framing. A large registry-based cohort study across Denmark, Finland, Norway, and Sweden found that girls who received the HPV vaccine were actually less likely to be hospitalized for infectious diseases compared to unvaccinated girls. The protective effect was consistent across all four countries.²⁶ This is not the first time a vaccine has shown broader effects beyond its target disease, but it is a striking finding that cuts against the narrative of hidden harm.

Even more striking, a global retrospective cohort study found that all-cause mortality was reduced by roughly half among HPV-vaccinated individuals over both 8-year and 20-year follow-up periods.²⁷ That figure likely reflects a combination of cancer prevention, the “healthy vaccinee” effect (where people who get vaccinated tend to be healthier overall), and possibly those non-specific protective effects seen in the Nordic data. It would be a mistake to attribute the entire mortality reduction to the vaccine itself. But the finding reinforces that in the population-level data, vaccinated individuals are not showing up sicker or dying earlier. They are doing the opposite.